NCT01133886

Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: King's College London · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the response rate at 6 months in Myelodysplastic Syndrome (MDS) patients, Chronic Myelomonocytic Leukaemia (CMML-2) patients, and Acute Myeloid Leukaemia (AML) patients with up to 30% bone marrow blasts, treated with low-dose decitabine who have previously failed therapy with 5-azacitidine.

Conditions

• Acute Myeloid Leukemia
• Chronic Myelomonocytic Leukemia
• Myelodysplastic Syndrome

Interventions

Type	Name	Description
DRUG	Decitabine	Patients will receive decitabine as a 20mg/m2 one hour intravenous infusion once daily on days 1 to 5 of a 4 week cycle.

Timeline

• Start date: 2010-09-01
• Primary completion: 2012-09-01
• Completion: 2013-09-01
• First posted: 2010-05-31
• Last updated: 2010-09-03

Locations

1 site across 1 country: United Kingdom